Downloads
Abstract
Hepatitis B is an infectious disease caused by the hepatitis B virus. In addition to liver damage, the disease can also affect other organs. For the kidneys, hepatitis B virus often causes glomerular damage and can lead to nephrotic syndrome. Diagnosing and treating glomerular diseases associate with hepatitis B virus remain challenging. In this article, we present the case of a 31 years old female patient with nephrotic syndrome related to hepatitis B virus, successfully treated at Thai Nguyen National Hospital.
| Published | 2025-06-27 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 4 No. 2 (2025) | |
| Section | Case reports | |
| DOI | 10.66517/jstmp.2025.2.1 | |
| Keywords | Hội chứng thận hư, Viêm gan virus B, Bệnh cầu thận màng Nephrotic syndrome, Hepatitis B, Membranous nephropathy |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Journal of Science and Technology in Medicine and Pharmacy
Shah, A. S. & Amarapurkar, D. N. Spectrum of hepatitis B and renal involvement. Liver Int 38, 23-32 (2018). https://doi.org:10.1111/liv.13498
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 100, S1-s276 (2021). https://doi.org:10.1016/j.kint.2021.05.021
Bộ Y tế. Hướng dẫn: CHẨN ĐOÁN VÀ ĐIỀU TRỊ BỆNH VIÊM GAN VI RÚT B (Ban hành kèm theo Quyết định số: 3310/QĐ-BYT ngày 29 tháng 7 năm 2019 của Bộ trưởng Bộ Y tế. (2019).
Mazzaro, C. et al. Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy. J Clin Med 11 (2022). https://doi.org:10.3390/jcm11216247
Buti, M. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1, 196-206 (2016). https://doi.org:10.1016/s2468-1253(16)30107-8
Lampertico, P. et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol 5, 441-453 (2020). https://doi.org:10.1016/s2468-1253(19)30421-2
Hann, H. W., Gregory, V. L., Dixon, J. S. & Barker, K. F. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int 2, 440-456 (2008). https://doi.org:10.1007/s12072-008-9105-y
Berchtold, L. et al. Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy. Kidney Int Rep 3, 486-491 (2018). https://doi.org:10.1016/j.ekir.2017.09.009